tetano
Editor, Senior Moderator
Cell Mol Life Sci
. 2022 May 21;79(6):309.
doi: 10.1007/s00018-022-04309-y.
Role of LL-37 in thrombotic complications in patients with COVID-19
Zilei Duan[SUP] #[/SUP][SUP] 1 2 [/SUP], Juan Zhang[SUP] #[/SUP][SUP] 3 [/SUP], Xue Chen[SUP] #[/SUP][SUP] 1 2 [/SUP], Ming Liu[SUP] #[/SUP][SUP] 1 2 [/SUP], Hongwen Zhao[SUP] 3 [/SUP], Lin Jin[SUP] 1 2 [/SUP], Zhiye Zhang[SUP] 1 2 [/SUP], Ning Luan[SUP] 2 [/SUP], Ping Meng[SUP] 4 [/SUP], Jing Wang[SUP] 5 [/SUP], Zhaoxia Tan[SUP] 3 [/SUP], Yaxiong Li[SUP] 6 [/SUP], Guohong Deng[SUP] 7 [/SUP], Ren Lai[SUP] 8 9 [/SUP]
Affiliations
Abstract
Blood clot formation induced by dysfunctional coagulation is a frequent complication of coronavirus disease 2019 (COVID-19) and a high-risk factor for severe illness and death. Neutrophil extracellular traps (NETs) are implicated in COVID-19-induced immunothrombosis. Furthermore, human cathelicidin, a NET component, can perturb the interaction between the SARS-CoV-2 spike protein and its ACE2 receptor, which mediates viral entry into cells. At present, however, the levels of cathelicidin antimicrobial peptides after SARS-CoV-2 infection and their role in COVID-19 thrombosis formation remain unclear. In the current study, we analyzed coagulation function and found a decrease in thrombin time but an increase in fibrinogen level, prothrombin time, and activated partial thromboplastin time in COVID-19 patients. In addition, the cathelicidin antimicrobial peptide LL-37 was upregulated by the spike protein and significantly elevated in the plasma of patients. Furthermore, LL-37 levels were negatively correlated with thrombin time but positively correlated with fibrinogen level. In addition to platelet activation, cathelicidin peptides enhanced the activity of coagulation factors, such as factor Xa (FXa) and thrombin, which may induce hypercoagulation in diseases with high cathelicidin peptide levels. Injection of cathelicidin peptides promoted the formation of thrombosis, whereas deletion of cathelicidin inhibited thrombosis in vivo. These results suggest that cathelicidin antimicrobial peptide LL-37 is elevated during SARS-CoV-2 infection, which may induce hypercoagulation in COVID-19 patients by activating coagulation factors.
Keywords: COVID-19; Coagulation factors; Hypercoagulation; LL-37; SARS-CoV-2.
. 2022 May 21;79(6):309.
doi: 10.1007/s00018-022-04309-y.
Role of LL-37 in thrombotic complications in patients with COVID-19
Zilei Duan[SUP] #[/SUP][SUP] 1 2 [/SUP], Juan Zhang[SUP] #[/SUP][SUP] 3 [/SUP], Xue Chen[SUP] #[/SUP][SUP] 1 2 [/SUP], Ming Liu[SUP] #[/SUP][SUP] 1 2 [/SUP], Hongwen Zhao[SUP] 3 [/SUP], Lin Jin[SUP] 1 2 [/SUP], Zhiye Zhang[SUP] 1 2 [/SUP], Ning Luan[SUP] 2 [/SUP], Ping Meng[SUP] 4 [/SUP], Jing Wang[SUP] 5 [/SUP], Zhaoxia Tan[SUP] 3 [/SUP], Yaxiong Li[SUP] 6 [/SUP], Guohong Deng[SUP] 7 [/SUP], Ren Lai[SUP] 8 9 [/SUP]
Affiliations
- PMID: 35596804
- DOI: 10.1007/s00018-022-04309-y
Abstract
Blood clot formation induced by dysfunctional coagulation is a frequent complication of coronavirus disease 2019 (COVID-19) and a high-risk factor for severe illness and death. Neutrophil extracellular traps (NETs) are implicated in COVID-19-induced immunothrombosis. Furthermore, human cathelicidin, a NET component, can perturb the interaction between the SARS-CoV-2 spike protein and its ACE2 receptor, which mediates viral entry into cells. At present, however, the levels of cathelicidin antimicrobial peptides after SARS-CoV-2 infection and their role in COVID-19 thrombosis formation remain unclear. In the current study, we analyzed coagulation function and found a decrease in thrombin time but an increase in fibrinogen level, prothrombin time, and activated partial thromboplastin time in COVID-19 patients. In addition, the cathelicidin antimicrobial peptide LL-37 was upregulated by the spike protein and significantly elevated in the plasma of patients. Furthermore, LL-37 levels were negatively correlated with thrombin time but positively correlated with fibrinogen level. In addition to platelet activation, cathelicidin peptides enhanced the activity of coagulation factors, such as factor Xa (FXa) and thrombin, which may induce hypercoagulation in diseases with high cathelicidin peptide levels. Injection of cathelicidin peptides promoted the formation of thrombosis, whereas deletion of cathelicidin inhibited thrombosis in vivo. These results suggest that cathelicidin antimicrobial peptide LL-37 is elevated during SARS-CoV-2 infection, which may induce hypercoagulation in COVID-19 patients by activating coagulation factors.
Keywords: COVID-19; Coagulation factors; Hypercoagulation; LL-37; SARS-CoV-2.